FDA clears new Physio-Control defibrillator/monitor

Physio-Control, a wholly owned subsidiary of Medtronic, has received clearance by the FDA to market the LIFEPAK 20e defibrillator/monitor within the U.S.

The 20e is an enhancement of the LIFEPAK 20 defibrillator/monitor, offering the capabilities of the LIFEPAK 20 device, along with a more powerful lithium-ion battery, according to the Redmond, Wash.-based Physio. Additionally, a new on-screen fuel gauge displays the real-time status of available battery capacity so clinicians can monitor remaining use time.

The company said its 20e also was developed to be easily transported, helping hospitals meet the Joint Commission standard.

Around the web

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.